A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

NCT07285902 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

572

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: HRS9531 injection
DRUG: Semaglutide Injection

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.